Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34467314 | 0.82 | DAGLA (0.51) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL11937844 | 0.81 | DAGLA (0.45) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL5783345 | 0.81 | CES1 (0.47) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL8614226 | 0.75 | — | — | |
| SCHEMBL9911978 | 0.69 | PTGS2 (0.40) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL3250812 | 0.68 | CES1 (0.33) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL1807276 | 0.68 | CES1 (0.45) | CES1DAGLALMNATSHRSMN1; SMN2 | |
| SCHEMBL18711785 | 0.67 | ITGB2 (0.47) | CYP1A2CYP2C9CNR2TSHRSMN1; SMN2 | |
| SCHEMBL25144893 | 0.67 | FPR3 (0.34) | DAGLA | |
| SCHEMBL9891803 | 0.66 | CYP1A2 (0.49) | CYP1A2CYP2C9GRM1LTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | CES1 113/4885NCEH1 382/4885DAGLA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.